Redecol Limited’s board appoints Hyman Capital as advisor to its fund raising activities
The Board of Redecol Limited has pleasure in announcing it is approaching the private market to raise £ 2m to fund clinical trials and then take the product to market. The board has selected Hyman Capital to advise on this process.
Redecol Limited has been established to research, develop and commercialise unique sensor technology for the monitoring and managing of asthma and other chronic respiratory conditions which will radically improve patient’s lives and reduce the cost burden of these chronic diseases for health service providers.
Redecol Limited is excited to report that they have appointed Hyman Capital as advisor to its fund-raising activities. Redecol Limited is working with Hyman Capital, to identify potential investors to raise the £ 2m.
Graham Hine said, “We selected Hyman Capital because of their strong record of raising funding to grow successful businesses and also because they understand the potential of Redecol to help improve the lives of millions of asthma sufferers.”
Clive Hyman said, “We are glad to be working with Redecol Limited, we have taken the time to understand the business and are working hand in glove with the management team to explain the benefits of their invention in their materials.”
Enquiries welcomed:
Graham Hine, Redecol Limited – +44 (0) 7774 257 333
Clive Hyman, Hyman Capital – +44 (0)7388 245 446